loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Naporafenib

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Naporafenib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Erasca To Present SEACRAFT-1 Phase 1 Data At EORTC Symposium
    Erasca To Present SEACRAFT-1 Phase 1 Data At EORTC Symposium

    25 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/25/2952906/0/en/Erasca-to-Present-Preliminary-SEACRAFT-1-Phase-1-Data-for-Naporafenib-Plus-Trametinib-in-RAS-Q61X-Mutant-Solid-Tumors-as-Oral-Presentation-at-36th-EORTC-NCI-AACR-Symposium.html

    GLOBENEWSWIRE
    25 Sep 2024
    Share Share
    Erasca Reports Second Quarter 2024 Business Updates and Financial Results
    Erasca Reports Second Quarter 2024 Business Updates and Financial Results

    12 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/12/2928728/0/en/Erasca-Reports-Second-Quarter-2024-Business-Updates-and-Financial-Results.html

    GLOBENEWSWIRE
    12 Aug 2024
    Share Share
    Erasca Initiates SEACRAFT-2 Phase 3 Trial For Naporafenib InMutant Melanoma
    Erasca Initiates SEACRAFT-2 Phase 3 Trial For Naporafenib InMutant Melanoma

    18 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/18/2900371/0/en/Erasca-Initiates-SEACRAFT-2-Pivotal-Phase-3-Trial-Evaluating-Naporafenib-Plus-Trametinib-in-Patients-with-NRAS-Mutant-Melanoma.html

    GLOBENEWSWIRE
    18 Jun 2024
    Share Share
    Erasca Reports Fourth Quarter 2023 and Full Year 2023 Financial Results
    Erasca Reports Fourth Quarter 2023 and Full Year 2023 Financial Results

    27 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/03/27/2853585/0/en/Erasca-Reports-Fourth-Quarter-2023-and-Full-Year-2023-Business-Updates-and-Financial-Results.html

    GLOBENEWSWIRE
    27 Mar 2024
    Share Share
    Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib
    Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib

    11 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/11/2793788/0/en/Erasca-Granted-FDA-Fast-Track-Designation-for-Pan-RAF-Inhibitor-Naporafenib-in-Patients-with-Advanced-NRAS-Mutated-Melanoma.html

    GLOBENEWSWIRE
    11 Dec 2023
    Share Share
    Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs
    Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs

    28 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/11/28/2786879/0/en/Erasca-Achieves-Key-Milestones-for-Naporafenib-and-ERAS-801-Programs-and-Extends-Cash-Runway.html

    GLOBENEWSWIRE
    28 Nov 2023
    Share Share